RECURSION PHARMACEUTICALS-A (RXRX) Fundamental Analysis & Valuation

NASDAQ:RXRX • US75629V1044

Current stock price

3.17 USD
0 (0%)
At close:
3.13 USD
-0.04 (-1.26%)
After Hours:

This RXRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RXRX Profitability Analysis

1.1 Basic Checks

  • In the past year RXRX has reported negative net income.
  • In the past year RXRX has reported a negative cash flow from operations.
  • In the past 5 years RXRX always reported negative net income.
  • In the past 5 years RXRX always reported negative operating cash flow.
RXRX Yearly Net Income VS EBIT VS OCF VS FCFRXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -200M -400M -600M

1.2 Ratios

  • RXRX's Return On Assets of -43.74% is in line compared to the rest of the industry. RXRX outperforms 54.14% of its industry peers.
  • With a decent Return On Equity value of -57.01%, RXRX is doing good in the industry, outperforming 60.31% of the companies in the same industry.
Industry RankSector Rank
ROA -43.74%
ROE -57.01%
ROIC N/A
ROA(3y)-41.98%
ROA(5y)-38.13%
ROE(3y)-57.54%
ROE(5y)-51.25%
ROIC(3y)N/A
ROIC(5y)N/A
RXRX Yearly ROA, ROE, ROICRXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80

1.3 Margins

  • RXRX has a Gross Margin of 4.99%. This is in the better half of the industry: RXRX outperforms 70.91% of its industry peers.
  • RXRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 4.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RXRX Yearly Profit, Operating, Gross MarginsRXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K -2.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. RXRX Health Analysis

2.1 Basic Checks

  • RXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RXRX has been increased compared to 1 year ago.
  • Compared to 5 years ago, RXRX has more shares outstanding
  • Compared to 1 year ago, RXRX has an improved debt to assets ratio.
RXRX Yearly Shares OutstandingRXRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
RXRX Yearly Total Debt VS Total AssetsRXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 500M 1B

2.2 Solvency

  • Based on the Altman-Z score of 0.09, we must say that RXRX is in the distress zone and has some risk of bankruptcy.
  • RXRX's Altman-Z score of 0.09 is fine compared to the rest of the industry. RXRX outperforms 60.50% of its industry peers.
  • RXRX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • RXRX has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 0.09
ROIC/WACCN/A
WACC9.31%
RXRX Yearly LT Debt VS Equity VS FCFRXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • RXRX has a Current Ratio of 5.50. This indicates that RXRX is financially healthy and has no problem in meeting its short term obligations.
  • RXRX's Current ratio of 5.50 is in line compared to the rest of the industry. RXRX outperforms 58.77% of its industry peers.
  • RXRX has a Quick Ratio of 5.50. This indicates that RXRX is financially healthy and has no problem in meeting its short term obligations.
  • RXRX's Quick ratio of 5.50 is in line compared to the rest of the industry. RXRX outperforms 59.92% of its industry peers.
Industry RankSector Rank
Current Ratio 5.5
Quick Ratio 5.5
RXRX Yearly Current Assets VS Current LiabilitesRXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RXRX Growth Analysis

3.1 Past

  • RXRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.84%, which is quite good.
  • RXRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.92%.
  • The Revenue has been growing by 79.93% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)10.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.38%
Revenue 1Y (TTM)26.92%
Revenue growth 3Y23.3%
Revenue growth 5Y79.93%
Sales Q2Q%687.79%

3.2 Future

  • Based on estimates for the next years, RXRX will show a small growth in Earnings Per Share. The EPS will grow by 7.80% on average per year.
  • The Revenue is expected to grow by 42.64% on average over the next years. This is a very strong growth
EPS Next Y33.75%
EPS Next 2Y18.88%
EPS Next 3Y10.67%
EPS Next 5Y7.8%
Revenue Next Year33.31%
Revenue Next 2Y55.99%
Revenue Next 3Y34.09%
Revenue Next 5Y42.64%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RXRX Yearly Revenue VS EstimatesRXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
RXRX Yearly EPS VS EstimatesRXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. RXRX Valuation Analysis

4.1 Price/Earnings Ratio

  • RXRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year RXRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXRX Price Earnings VS Forward Price EarningsRXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXRX Per share dataRXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.88%
EPS Next 3Y10.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RXRX Dividend Analysis

5.1 Amount

  • No dividends for RXRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RXRX Fundamentals: All Metrics, Ratios and Statistics

RECURSION PHARMACEUTICALS-A

NASDAQ:RXRX (3/25/2026, 8:00:02 PM)

After market: 3.13 -0.04 (-1.26%)

3.17

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-04
Inst Owners64.21%
Inst Owner Change0.16%
Ins Owners2.56%
Ins Owner Change5.96%
Market Cap1.67B
Revenue(TTM)74.68M
Net Income(TTM)-644.76M
Analysts74.29
Price Target7.14 (125.24%)
Short Float %33.24%
Short Ratio8.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.7%
Min EPS beat(2)4.61%
Max EPS beat(2)34.79%
EPS beat(4)3
Avg EPS beat(4)7.8%
Min EPS beat(4)-14.85%
Max EPS beat(4)34.79%
EPS beat(8)6
Avg EPS beat(8)3.35%
EPS beat(12)9
Avg EPS beat(12)2.52%
EPS beat(16)11
Avg EPS beat(16)-24.3%
Revenue beat(2)1
Avg Revenue beat(2)-14.21%
Min Revenue beat(2)-70.13%
Max Revenue beat(2)41.71%
Revenue beat(4)2
Avg Revenue beat(4)-6.63%
Min Revenue beat(4)-70.13%
Max Revenue beat(4)41.71%
Revenue beat(8)4
Avg Revenue beat(8)-13.01%
Revenue beat(12)4
Avg Revenue beat(12)-16.53%
Revenue beat(16)6
Avg Revenue beat(16)-13.25%
PT rev (1m)0%
PT rev (3m)10.53%
EPS NQ rev (1m)21.18%
EPS NQ rev (3m)22.74%
EPS NY rev (1m)15.36%
EPS NY rev (3m)23.51%
Revenue NQ rev (1m)7.24%
Revenue NQ rev (3m)7.24%
Revenue NY rev (1m)-0.74%
Revenue NY rev (3m)3.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.39
P/FCF N/A
P/OCF N/A
P/B 1.48
P/tB 2.54
EV/EBITDA N/A
EPS(TTM)-1.48
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0.14
BVpS2.14
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.74%
ROE -57.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 4.99%
FCFM N/A
ROA(3y)-41.98%
ROA(5y)-38.13%
ROE(3y)-57.54%
ROE(5y)-51.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.73%
Cap/Sales 8.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.5
Quick Ratio 5.5
Altman-Z 0.09
F-Score4
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)31.42%
Cap/Depr(5y)176.53%
Cap/Sales(3y)19.59%
Cap/Sales(5y)108.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.38%
EPS Next Y33.75%
EPS Next 2Y18.88%
EPS Next 3Y10.67%
EPS Next 5Y7.8%
Revenue 1Y (TTM)26.92%
Revenue growth 3Y23.3%
Revenue growth 5Y79.93%
Sales Q2Q%687.79%
Revenue Next Year33.31%
Revenue Next 2Y55.99%
Revenue Next 3Y34.09%
Revenue Next 5Y42.64%
EBIT growth 1Y-35.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.63%
EBIT Next 3Y12.18%
EBIT Next 5YN/A
FCF growth 1Y-1.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.52%
OCF growth 3YN/A
OCF growth 5YN/A

RECURSION PHARMACEUTICALS-A / RXRX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of RECURSION PHARMACEUTICALS-A (RXRX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RXRX.


What is the valuation status for RXRX stock?

ChartMill assigns a valuation rating of 0 / 10 to RECURSION PHARMACEUTICALS-A (RXRX). This can be considered as Overvalued.


Can you provide the profitability details for RECURSION PHARMACEUTICALS-A?

RECURSION PHARMACEUTICALS-A (RXRX) has a profitability rating of 1 / 10.


How financially healthy is RECURSION PHARMACEUTICALS-A?

The financial health rating of RECURSION PHARMACEUTICALS-A (RXRX) is 4 / 10.